Abstract
A combination of Western blot, Northern blot, and radiolabeled ligand-binding techniques was used to investigate retinoid-binding proteins in retinoblastoma (RB) cells from fresh tumors and from 19 RB tumor lines cultured in vitro. Using rabbit anti-bovine cellular retinal-binding protein (CRA1BP) antibodies, no CRA1BP could be detected. As determined by [3H]retinol binding, cellular retinol-binding protein was sometimes not detectable but averaged 2.3 ± 2.7 x̄ ± SD, n = 7) pmol [3H]retinol bound/mg protein, similar to adult retina cytosol. Using [3H]retinoic acid as ligand, cellular retinoic acid-binding protein was not detectable in some lines and averaged 1.0 ± 1.2 (x̄ ± SD, n = 7) pmol [3H]retinoic acid bound/mg protein, well below the adult retina cytosol level of 94.4 ± 16.3 (x̄ ± SD, n = 4) pmol [3H]retinoic acid bound/mg. Using rabbit antibovine interstitial retinol-binding protein (IRBP) antibodies, IRBP of the same molecular mass as human IRBP (135,000) was detected in the medium from all cultured RB cells and averaged 75.9 ± 19.2 pmol/108 cells (bovine IRBP immunochemical equivalents). Cytosol levels were less than 1% of the medium. Using a human IRBP complementary DNA probe, levels of IRBP RNA transcripts in 19 RB cell lines were comparable to adult retina. The Y-79 RB cell line was different from the others; the amount of IRBP in the medium was only about 1% of the RB cell lines. Levels of cellular retinol-binding protein were comparable with the other lines, but cellular retinoic acid-binding protein was 9 times more abundant. IRBP RNA transcripts in Y-79 cells were below the limits of detectability but appeared at low levels after induction of differentiation of Y-79 by 10-6 m retinoic acid. Although this cell line has been in culture longer than the others, it may also have been initiated at an earlier stage of retinal development.
Footnotes
-
↵1 Supported by the Retina Research Foundation of Houston, Knights Templar Eye Foundation, Inc., NIH EY 02489 and EY 02520, and Hospital for Sick Children Foundation (Toronto), the Medical Research Council of Canada, National Cancer Institute of Canada.
-
↵2 To whom requests for reprints should be addressed.
- Received August 19, 1987.
- Revision received November 20, 1987.
- Accepted December 1, 1987.
- ©1988 American Association for Cancer Research.